Abstract: The invention relates to a nicotine chewing gum giving an immediate release and uptake of nicotine as well as an extended release and uptake of nicotine as well as describing suitable manufacturing processes for such chewing gum formulations and the use of the chewing gum for the treatment of a human being suffering from cravings from tobacco and/or e-cigarette dependency.

Abstract: The present disclosure relates to self-emulsifying pharmaceutical compositions for transmucosal delivery of biologically active peptides and proteins.

Abstract: Methods for alleviating one or more symptoms and/or inhibiting muscle disuse atrophy in mammals via administration of compositions of egg powder protein are provided.

Abstract: Provided is a green tea-containing beverage including: (A) green tea; (B) at least one selected from the group consisting of phytic acid, tartaric acid, and gluconic acid; and (C) at least one selected from the group consisting of ascorbic acid, a salt of ascorbic acid, erythorbic acid, and a salt of erythorbic acid, wherein the green tea-containing beverage has a copper content of 0.3 mg/L or more. Preferably, the concentration of the constituent (B) is 0.05-2.5 g/L. Preferably, the concentration of the constituent (C) is 0.2-5 g/L. Preferably the green tea-containing beverage further includes alcohol. Also provided is a method for preventing discoloration of a green tea-containing beverage, the method including: incorporating the constituents (B) and (C) in the green tea-containing beverage; and further incorporating copper so as to give the copper content of 0.3 mg/L or more.

Abstract: The present invention is directed to a soft chewable composition comprising or containing a therapeutically effective amount of a veterinary active agent, preferably a JAK inhibitor; an animal based palatant, a non-animal based palatant, a flavor modifier, and at least one veterinary acceptable excipient that is selected from at least one each of a disintegrant, binder, lubricant, humectant, and glidant; and wherein the soft chewable tablet is compressed with a rotary tablet press; and methods for treating or preventing cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergies, and chronic respiratory disease in an animal.

Abstract: Pet food compositions and methods for increasing body weight and decreasing indoles in a feline having renal insufficiency are provided. The methods may include feeding the feline an effective amount of the pet food composition. The pet food composition may include fermentable fibers and betaine.

Abstract: A nutritional supplement is described that is useful in combination with radiotherapy to reduce the growth of tumor stem cells. The nutritional supplement includes selenium and fish oil, and has been also found to be effective in reducing negative side effects of concurrent radiotherapy, including inflammation, weight loss, muscle wasting, neutropenia, and loss of cells from the lining of the gut.

Abstract: Sweetener compositions having particular glycoside compositions are described herein. The glycoside compositions include rebaudioside D and/or rebaudioside M that are combined with other glycosides such as rebaudioside E, rebaudioside G, rebaudioside N and/or rebaudioside O. The sweetener compositions can also include one or more bulking agents or other ingredients. The sweetener compositions can be used in foods and beverages.

Abstract: A composition configured for oral use is provided, the composition including a filler in an amount of at least 20% by weight, based on the total weight of the composition, and at least one active ingredient including one or more botanical materials, stimulants, amino acids, vitamins, antioxidants, cannabinoids, pharmaceutical agents, or a combination thereof. The composition further includes a salt and at least one sweetener. The composition has a moisture content of at least about 40% by weight, based on the total weight of the composition.

Abstract: Methods and products related to a cereal product having a water activity of about 0.4 or more and an SAG content of greater than about 15 g per 100 g of cereal product.

Abstract: In various embodiments of the present disclosure, compositions exhibiting metabolism boosting effect are described. In various examples, compositions comprise a synergistic combination of at least one plant, root, seed, or fruit material, or extract thereof, or bioactive therefrom; at least one vitamin, essential trace mineral, or enzyme or vitamin cofactor; at least one amino acid; and at least one antioxidant. In various aspects, metabolism enhancing compositions are formulated as loose powders filled into capsules as orally administered dietary supplements. In various embodiments, compositions of the present disclosure are used to treat metabolic syndrome in subjects expressing symptoms thereof.

Abstract: Provided is a composition for preventing or ameliorating a functional gastrointestinal disorder whose active ingredient is Bifidobacterium breve MCC1274 (FERM BP-11175). A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can prevent or improve constipation or frequent bowel movements, regulate the number of bowel movements, improve stool quality, prevent or improve constipation, prevent or ameliorate bloating, or prevent or improve abdominal discomfort. Disclosed is a composition for preventing or ameliorating a functional gastrointestinal disorder accompanied by anxiety disorder. A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can be used in a pharmaceutical composition or in a food or beverage composition.

Abstract: A pet food composition specifically formulated for a small dog can include a combination of specific amino acids and probiotics to maintain or increase absorption of amino acids. Methods of increasing absorption of amino acids are also provided.

Abstract: A specific type of organ health marker in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the specific type of organ health marker or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates the specific type of organ health marker. The specific type of organ health marker can be one or more of phosphorus, alkaline phosphatase, aspartate aminotransferase, or gamma-glutamyltransferase.

Abstract: Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers.

Abstract: The invention provides a method for providing a non-uniform pigment distribution in a first plant part (110) of a pigment generating plant (100), which accumulates pigment upon exposure by light, during indoor cultivation of said plant (100), wherein the first plant part (110) comprises a second plant part (120) and a third plant part (130), the method comprising subjecting in a first lighting stage at least the first plant part (110) to first light conditions that inhibit or prevent pigment accumulation in said first plant part (110), and subsequently subjecting in a second lighting stage the second plant part (120) of said first plant part (110) to second light conditions that promote pigment accumulation in said second plant part (120) while subjecting the third plant part (130) of said first plant part (110) to third light conditions that inhibit or prevent pigment accumulation in said third plant part (130).

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hair loss, a health functional food composition or a cosmetic composition, including a specific compound or a pharmaceutically acceptable salt thereof as an active ingredient, wherein the compound exhibits an excellent hair growth recovery effect in hair follicle tissues in which hair growth is inhibited without cytotoxicity, and thus hair loss can be more effectively prevented, improved, or treated.

Abstract: The invention relates to an agent for use in the prophylaxis or treatment of dyslipidemia, in particular for the treatment of excessive/elevated LDL levels, containing propionic acid or a physiologically acceptable propionic acid derivative.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, pharmaceutical composition comprising at least one controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate or solvate thereof, for use in the treatment, control, delay or prevention of a condition that can be treated, controlled, delayed or prevented with PTH, wherein said pharmaceutical composition is administered no more frequently than once every 24 hours with a dosage of the controlled-release PTH compound that corresponds to no more than 70% of the molar equivalent dose of PTH 1-84 administered every 24 hours required to maintain serum calcium within normal levels over said 24 hour period in humans.

Abstract: The invention provides compositions and methods for metabolic health in an animal comprising administering a non-ketogenic composition to the animal, wherein the non-ketogenic composition comprises about 5% to about 25% carbohydrates, about 30% to about 60% protein, and about 10% to about 40% fat. Additionally, the composition can have a protein to carbohydrate ratio of at least 2:1.

Abstract: The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.

Abstract: A method for treating autoimmune and/or inflammatory diseases includes a step of identifying a subject having a gastrointestinal autoimmune/inflammatory disease. A fasting mimicking diet (FMD) is administered to the subject for a first time period.

Abstract: A smokeless tobacco product is provided that includes a tobacco material in the form of a tobacco extract, a particulate tobacco material, or a combination thereof. In some embodiments, the smokeless tobacco product is substantially translucent. Methods for making and using the smokeless tobacco product are also provided. The smokeless tobacco product can include isomalt, maltitol syrup, particulate tobacco, and a translucent tobacco extract prepared by ultrafiltration.

Abstract: The present invention concerns novel Lactobacillus plantarum strains capable of promoting the growth of a subject, and more particularly the juvenile or prenatal growth of farm animals, and their uses as probiotics.

Abstract: A pharmaceutical composition of the present invention is used for improving health, cure abnormalities and degenerative disease; achieve anti-aging effect of therapy and therapeutic effect on mammals. The pharmaceutical composition includes a pharmaceutical carrier and an isotope selective ingredient including at least one of a chemical element and a chemical compound containing the chemical element whereby isotope distribution in the at least one of the chemical element and the chemical compound containing the chemical element is different from natural distribution of at least one of isotopes wherein the part of selected isotope of the chemical element ranges from 0 to 100%. A method of the present invention uses the inventive pharmaceutical composition to improve health, cure abnormalities and degenerative disease and achieve therapeutic effect on mammals.

Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of polysaccharides and nucleic acids have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight polysaccharides and nucleic acids, and viscosity-lowering agents.

Abstract: Suspensions of metronidazole or baclofen and/or salts or ester derivative thereof, such as metronidazole benzoate, are disclosed. The suspension my include metronidazole or baclofen, and/or a salt or ester derivative thereof a hydrocolloid stabilizer, simethicone emulsion, a buffer, such as sodium citrate, (dihydrate), a preservative, a thickening agent, a sweetener, and water.

Abstract: A dosage form with a first portion and a second portion. The first portion can be an immediate release portion and can comprise a pain reliever, which can be naproxen or naproxen sodium. The second portion can be an extended release portion and can comprise pseudoephedrine or a pharmaceutically acceptable salt thereof and/or dextromethorphan or a pharmaceutically acceptable salt thereof. The dosage form can optionally comprise a stabilizing agent. The dosage form can be adapted to maintain a therapeutically effective amount of pain reliever, pseudoephedrine, or a pharmaceutically acceptable salt thereof, and/or dextromethorphan, or a pharmaceutically acceptable salt thereof, for at least eight hours.

Abstract: To help consumers around the world reduce the confusion and complexity of choosing among thousands of wellness products that are effective for their particular medical conditions and/or wellness goals, the present inventor, devised one or more exemplary systems, methods, software, and data structures for recommending products, such as health, fitness, and nutritional products, to consumers. One exemplary system receives user profile information, such as gender, age, medical condition(s), wellness goal(s), biometric data, allergies and sensitivities, and/or nutrition information, and recommends products based on the consumer profiles and product ingredient efficacy and/or contraindications for the medical conditions and/or wellness goals. The system recommends the most scientifically effective products for a particular consumer, while accounting for contraindications thereby reducing risk potentially harmful products.

Abstract: The present invention relates to a composition for the protection, treatment and repair of cartilage in humans and animal joints. The composition contains a combination of unsaponifiable lipids together with one or more of polyphenols and/or catechins. The composition or kit may contain avocado:soybean unsaponifiables (ASU) and green tea.

Abstract: Storage stable sterile ready-to-administer formulations comprising N-acetylcysteine are presented with desirable stability characteristics. In preferred aspects, formulations comprise low quantities of one or more chelating agents, contain N-acetylcysteine at a concentration of 25 mg/mL or 50 mg/mL, and are packaged in a suitable format, such as a polymeric bag with a metalized overwrap and a non-contact oxygen scavenger.

Abstract: Disclosed herein are formulations suitable for parenteral administration of certain hydrophobic active agents such as Coenzyme Q10. Methods of preparing the same and methods of treatment of oncological disorders using the same are also provided herein. The formulations comprise an aqueous solution; a hydrophobic active agent dispersed to form a colloidal nano-dispersion of particles; and at least one of a dispersion stabilizing agent and an opsonization reducer wherein the colloidal nano-dispersion of the active agent is dispersed into nano-dispersion particles having a mean size of less than 200-nm. Methods of preparing the parenteral formulations comprise dispersing the hydrophobic active agent by high pressure homogenization by (1) adding hydrophobic active agent to a 65° C. bath of water and mixing to form a hydrophobic active agent/water mixture; (2) adding a dispersion stabilizing agent to the hydrophobic active agent/water mixture and mix at 65° C.

Abstract: The invention provides compositions and methods for topically inhibiting, reducing or preventing growth or biofilm formation of caries-, gingivitis- and/or halitosis-causing bacteria. The composition includes at least about 0.005% (w/v) of tea polyphenols, a pH modulating agent for maintaining a pH of the composition above about 6.5, and at least about 1% (w/v) of a 3-carbon to a 24-carbon sugar alcohol. Also provided are food products or supplements incorporating such compositions.

Abstract: Compositions including herbal extracts, such as a Vitex negundo extract, a Cardiospermum halicacabum extract, and a Bambusa arundinacea extract, and methods using such compositions are disclosed. For example, compositions and methods may be used to improve joint health.

Abstract: A method of encapsulating content with calcium alginate membrane to form a capsule. The method includes embedding sodium alginate into a traditional gelatin ribbon used in gelatin encapsulation, adding calcium to a fill material, encapsulating the fill material, and then denaturing the gelatin in the shell. An exemplary use of this method is to form throwable paintballs; however, other products could be formed using this process. A paintball formed by this process is also disclosed.

Abstract: A composition useful for promoting a desired oral microbiota to treat an allergy related respiratory condition in a subject in need of such treatment, the composition including an amino acid containing ingredient including individual molecules of L-arginine; the composition in a configuration to be maintained within the oral cavity for a period of at least about 30 seconds to about an hour, the desired oral microbiota including Veillonella and Streptococcus.

Abstract: Medical devices and related augmented reality systems and methods are provided. A method of providing guidance to a patient using an electronic device having an imaging device associated therewith involves analyzing one or more images captured by the imaging device to identify image content indicative of a potential activity for the patient, determining, by a control system associated with the electronic device, one or more attributes for the potential activity, determining, by the control system, a predicted physiological response by the patient to the potential activity based at least in part on the one or more attributes, and providing, on a display associated with the electronic device, an augmented reality graphical user interface including a graphical indication influenced by the predicted physiological response.

Abstract: An eggless mayo is provided that is heat stable or that is heat stable as well as freeze-thaw stable and that is all natural. In addition a mayonnaise composition is provided that has increased heat stability as well as freeze-thaw stability. A low-salt version of the eggless mayo is provided as well as compositions for various butters and creams that have enhanced heat stability as well as freeze-thaw stability.

Abstract: UHT treated liquid nutritional compositions are provided having a high caloric content of around 2.0 kcal/ml and higher, a savoury taste and comprising protein, carbohydrate and fat components. The nutritional compositions are for use in the treatment of patients having high energy needs.

Abstract: The invention provides compositions and methods for utilizing oligosaccharides, such as isolated human milk oligosaccharides, to attenuate a respiratory pathogen infection and/or to promote recovery from a respiratory pathogen infection in the respiratory system and/or the GI tract of a subject.

Abstract: Methods and egg yolk powder containing compositions for improving skeletal muscle protein fractional synthetic rate (FSR) in mammals and inhibiting or reversing sarcopenia are provided.

Abstract: This disclosure provides a dry powder formulation of free amino acids with an acceptable and even good taste profile.

Abstract: A chewable pharmaceutical product comprises a matrix comprising: a binder, a bulking agent, a lubricant, a humectant, an emulsifier, and optionally a flavoring, wherein the binder comprises one or more maltitol syrups, which are present in the pharmaceutical product in an amount in the range of 60-70% by weight; and colesevelam hydrochloride.

Abstract: Compositions for oral administration and processes of preparing the same are described. In particular, compositions in the form of bilayer tablets including B vitamins for modified delivery are described. The bilayer multi-B vitamin tablets offer immediate release of a first set of B vitamins, such as riboflavin (B2) and cyanocobalamin (B12) followed by controlled release of a second set of B vitamins, such as folic acid, biotin, niacinamide (B3), pyridoxine (B6), pantothenic acid (B5) and thiamine (B1).

Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

Abstract: The present invention relates to an agent comprising anion-exchange groups that are suitable for adsorbing bacterial lipopolysaccharides (LPS) and/or lipoteichoic acids (LTA), for use in the prevention and/or treatment of inflammatory conditions and/or diseases of the oral cavity or in the vaginal region. The present invention also relates to a pharmaceutical composition that comprises an agent of this kind and can adhere to mucosa.

Abstract: The present invention provides a therapeutic composition comprising a synergistic combination of caffeine, Ginkgo biloba, and ?-phenylethylamine (PEA) or its salt. The invention is also directed to oral dosage forms containing said composition, and to a method of treatment of a psychological, psychiatric, behavioral and/or neurodevelopmental disorder comprising the administration of said compositions and dosage forms to a patient in need thereof.

Abstract: Disclosed is a method for evaluating the ability of a chemical substance or a chemical composition to prevent muscle fatigue and damage induced by physical exertion in humans; edible composition including at least one salt of a multivalent metal cation, at least one compound selected between vitamin E or vitamin E acetate, at least one edible polyphenol compound selected from compounds of the flavonol family, compounds of the anthocyanin family, compounds of the phenolic acid family and compounds of the flavonol family and/or the glucosylated derivatives thereof, in which the molar ratio/is of at least 0.50 and not more than 2.00; its use as a food supplement or for preparing a food supplement composition or as a drug for preventing muscle fatigue and/or muscle damage induced by physical exertion, in a method for the treatment of the human body by therapy.

Abstract: Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.

Abstract: Multi-dose packaged over-the-counter antitussive syrups comprise a bottle containing about 75 ml or less of a liquid formulation of dextromethorphan hydrobromide. The liquid formulation provides at least two doses of dextromethorphan hydrobromide. Multi-dose packaged over-the-counter liquid formulations comprise a bottle having a capacity of about 100 ml or less, at least two doses of the liquid formulation carried within the bottle, a cap, a dosage cup releasably carried on the cap and a shrink wrap substantially enveloping the bottle and the dosage cup. Antitussive syrups comprise water, dextromethorphan hydrobromide in amounts from about 6 to about 25 mg/ml, and sweetener in amounts from about 200 to about 800 mg/ml.